Asset
SOTROVIMAB
Vir Biotechnology Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04545060 | phase2_3 | completed | 2020-08-27 | 2021-04-08 | Vir Biotechnology, Inc. | VIR-7831 for the Early Treatment of COVID-19 in Outpatients |
FDA applications (0)
This company has no applications containing this asset.